{"transactions":[{"id":4638284,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Option to Purchase Common Stock","published_at":"2026-10-08T23:56:19.000Z","date":"2026-10-08","kind":"exercise","planned":true,"acquired":false,"shares":20000,"price":18.41,"value":368200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The\nsales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant\nwas February 14, 2018."}],"balance_after":21552,"derivative":{"exercise_price":18.41,"expiration_date":"2028-02-14","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001159036-26-000140","document":"wk-form4_1791503775.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1528185/000115903626000140/wk-form4_1791503775.xml","form_type":"4"}},{"id":4638283,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Option to Purchase Common Stock","published_at":"2026-10-08T23:56:19.000Z","date":"2026-10-07","kind":"exercise","planned":true,"acquired":false,"shares":20000,"price":18.41,"value":368200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The\nsales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant\nwas February 14, 2018."}],"balance_after":41552,"derivative":{"exercise_price":18.41,"expiration_date":"2028-02-14","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001159036-26-000140","document":"wk-form4_1791503775.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1528185/000115903626000140/wk-form4_1791503775.xml","form_type":"4"}},{"id":4638282,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Option to Purchase Common Stock","published_at":"2026-10-08T23:56:19.000Z","date":"2026-10-06","kind":"exercise","planned":true,"acquired":false,"shares":20000,"price":18.41,"value":368200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The\nsales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant\nwas February 14, 2018."}],"balance_after":61552,"derivative":{"exercise_price":18.41,"expiration_date":"2028-02-14","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001159036-26-000140","document":"wk-form4_1791503775.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1528185/000115903626000140/wk-form4_1791503775.xml","form_type":"4"}},{"id":4638281,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-10-08T23:56:19.000Z","date":"2026-10-08","kind":"sale","planned":true,"acquired":false,"shares":200,"price":110.51,"value":22102.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The\nsales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."}],"balance_after":767780,"source":{"system":"sec-edgar","filing":"0001159036-26-000140","document":"wk-form4_1791503775.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1528185/000115903626000140/wk-form4_1791503775.xml","form_type":"4"}},{"id":4638280,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-10-08T23:56:19.000Z","date":"2026-10-08","kind":"sale","planned":true,"acquired":false,"shares":11900,"price":109.995,"value":1308940.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The\nsales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $109.510 to $110.500. The Reporting Person has provided to the issuer, and will provide to any\nsecurity holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":767980,"source":{"system":"sec-edgar","filing":"0001159036-26-000140","document":"wk-form4_1791503775.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1528185/000115903626000140/wk-form4_1791503775.xml","form_type":"4"}},{"id":4638279,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-10-08T23:56:19.000Z","date":"2026-10-08","kind":"sale","planned":true,"acquired":false,"shares":3090,"price":108.908,"value":336525.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The\nsales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $108.480 to $109.470. The Reporting Person has provided to the issuer, and will provide to any\nsecurity holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":779880,"source":{"system":"sec-edgar","filing":"0001159036-26-000140","document":"wk-form4_1791503775.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1528185/000115903626000140/wk-form4_1791503775.xml","form_type":"4"}},{"id":4638278,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-10-08T23:56:19.000Z","date":"2026-10-08","kind":"sale","planned":true,"acquired":false,"shares":4810,"price":108.179,"value":520340.99,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The\nsales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $107.480 to $108.475. The Reporting Person has provided to the issuer, and will provide to any\nsecurity holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":782970,"source":{"system":"sec-edgar","filing":"0001159036-26-000140","document":"wk-form4_1791503775.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1528185/000115903626000140/wk-form4_1791503775.xml","form_type":"4"}},{"id":4638277,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-10-08T23:56:19.000Z","date":"2026-10-08","kind":"exercise","planned":true,"acquired":true,"shares":20000,"price":18.41,"value":368200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The\nsales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."}],"balance_after":787780,"source":{"system":"sec-edgar","filing":"0001159036-26-000140","document":"wk-form4_1791503775.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1528185/000115903626000140/wk-form4_1791503775.xml","form_type":"4"}},{"id":4638276,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-10-08T23:56:19.000Z","date":"2026-10-07","kind":"sale","planned":true,"acquired":false,"shares":200,"price":113.693,"value":22738.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The\nsales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $113.590 to $113.860. The Reporting Person has provided to the issuer, and will provide to any\nsecurity holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":767780,"source":{"system":"sec-edgar","filing":"0001159036-26-000140","document":"wk-form4_1791503775.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1528185/000115903626000140/wk-form4_1791503775.xml","form_type":"4"}},{"id":4638275,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-10-08T23:56:19.000Z","date":"2026-10-07","kind":"sale","planned":true,"acquired":false,"shares":900,"price":112.78,"value":101502.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The\nsales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $112.400 to $113.190. The Reporting Person has provided to the issuer, and will provide to any\nsecurity holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":767980,"source":{"system":"sec-edgar","filing":"0001159036-26-000140","document":"wk-form4_1791503775.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1528185/000115903626000140/wk-form4_1791503775.xml","form_type":"4"}},{"id":4638274,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-10-08T23:56:19.000Z","date":"2026-10-07","kind":"sale","planned":true,"acquired":false,"shares":10300,"price":111.839,"value":1151941.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The\nsales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $111.380 to $112.360. The Reporting Person has provided to the issuer, and will provide to any\nsecurity holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":768880,"source":{"system":"sec-edgar","filing":"0001159036-26-000140","document":"wk-form4_1791503775.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1528185/000115903626000140/wk-form4_1791503775.xml","form_type":"4"}},{"id":4638273,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-10-08T23:56:19.000Z","date":"2026-10-07","kind":"sale","planned":true,"acquired":false,"shares":8600,"price":111.031,"value":954866.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The\nsales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $110.360 to $111.350. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":779180,"source":{"system":"sec-edgar","filing":"0001159036-26-000140","document":"wk-form4_1791503775.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1528185/000115903626000140/wk-form4_1791503775.xml","form_type":"4"}},{"id":4638272,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-10-08T23:56:19.000Z","date":"2026-10-07","kind":"exercise","planned":true,"acquired":true,"shares":20000,"price":18.41,"value":368200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The\nsales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."}],"balance_after":787780,"source":{"system":"sec-edgar","filing":"0001159036-26-000140","document":"wk-form4_1791503775.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1528185/000115903626000140/wk-form4_1791503775.xml","form_type":"4"}},{"id":4638271,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-10-08T23:56:19.000Z","date":"2026-10-06","kind":"sale","planned":true,"acquired":false,"shares":1780,"price":110.812,"value":197245.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The\nsales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $110.530 to $111.210. The Reporting Person has provided to the issuer, and will provide to any\nsecurity holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":767780,"source":{"system":"sec-edgar","filing":"0001159036-26-000140","document":"wk-form4_1791503775.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1528185/000115903626000140/wk-form4_1791503775.xml","form_type":"4"}},{"id":4638270,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-10-08T23:56:19.000Z","date":"2026-10-06","kind":"sale","planned":true,"acquired":false,"shares":9920,"price":109.891,"value":1090118.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The\nsales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $109.530 to $110.510. The Reporting Person has provided to the issuer, and will provide to any\nsecurity holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":769560,"source":{"system":"sec-edgar","filing":"0001159036-26-000140","document":"wk-form4_1791503775.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1528185/000115903626000140/wk-form4_1791503775.xml","form_type":"4"}},{"id":4638269,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-10-08T23:56:19.000Z","date":"2026-10-06","kind":"sale","planned":true,"acquired":false,"shares":6000,"price":109.334,"value":656004.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The\nsales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $108.530 to $109.520. The Reporting Person has provided to the issuer, and will provide to any\nsecurity holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":779480,"source":{"system":"sec-edgar","filing":"0001159036-26-000140","document":"wk-form4_1791503775.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1528185/000115903626000140/wk-form4_1791503775.xml","form_type":"4"}},{"id":4638268,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-10-08T23:56:19.000Z","date":"2026-10-06","kind":"sale","planned":true,"acquired":false,"shares":2300,"price":107.902,"value":248174.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The\nsales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $107.480 to $108.290. The Reporting Person has provided to the issuer, and will provide to any\nsecurity holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":785480,"source":{"system":"sec-edgar","filing":"0001159036-26-000140","document":"wk-form4_1791503775.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1528185/000115903626000140/wk-form4_1791503775.xml","form_type":"4"}},{"id":4638267,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-10-08T23:56:19.000Z","date":"2026-10-06","kind":"exercise","planned":true,"acquired":true,"shares":20000,"price":18.41,"value":368200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The\nsales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."}],"balance_after":787780,"source":{"system":"sec-edgar","filing":"0001159036-26-000140","document":"wk-form4_1791503775.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1528185/000115903626000140/wk-form4_1791503775.xml","form_type":"4"}},{"id":4616544,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Option to Purchase Common Stock","published_at":"2026-09-12T00:35:17.000Z","date":"2026-09-11","kind":"exercise","planned":true,"acquired":false,"shares":20000,"price":18.41,"value":368200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The\nsales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of\ngrant was February 14, 2018."}],"balance_after":81552,"derivative":{"exercise_price":18.41,"expiration_date":"2028-02-14","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001159036-26-000119","document":"wk-form4_1789173314.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1528185/000115903626000119/wk-form4_1789173314.xml","form_type":"4"}},{"id":4616543,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Option to Purchase Common Stock","published_at":"2026-09-12T00:35:17.000Z","date":"2026-09-10","kind":"exercise","planned":true,"acquired":false,"shares":20000,"price":18.41,"value":368200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The\nsales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of\ngrant was February 14, 2018."}],"balance_after":101552,"derivative":{"exercise_price":18.41,"expiration_date":"2028-02-14","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001159036-26-000119","document":"wk-form4_1789173314.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1528185/000115903626000119/wk-form4_1789173314.xml","form_type":"4"}},{"id":4616542,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Option to Purchase Common Stock","published_at":"2026-09-12T00:35:17.000Z","date":"2026-09-09","kind":"exercise","planned":true,"acquired":false,"shares":20000,"price":18.41,"value":368200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The\nsales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of\ngrant was February 14, 2018."}],"balance_after":121552,"derivative":{"exercise_price":18.41,"expiration_date":"2028-02-14","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001159036-26-000119","document":"wk-form4_1789173314.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1528185/000115903626000119/wk-form4_1789173314.xml","form_type":"4"}},{"id":4616541,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-09-12T00:35:17.000Z","date":"2026-09-11","kind":"sale","planned":true,"acquired":false,"shares":4508,"price":107.548,"value":484826.384,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The\nsales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $107.400 to $107.960. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":767780,"source":{"system":"sec-edgar","filing":"0001159036-26-000119","document":"wk-form4_1789173314.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1528185/000115903626000119/wk-form4_1789173314.xml","form_type":"4"}},{"id":4616540,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-09-12T00:35:17.000Z","date":"2026-09-11","kind":"sale","planned":true,"acquired":false,"shares":15492,"price":107.154,"value":1660029.768,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The\nsales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $106.400 to $107.390. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":772288,"source":{"system":"sec-edgar","filing":"0001159036-26-000119","document":"wk-form4_1789173314.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1528185/000115903626000119/wk-form4_1789173314.xml","form_type":"4"}},{"id":4616539,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-09-12T00:35:17.000Z","date":"2026-09-11","kind":"exercise","planned":true,"acquired":true,"shares":20000,"price":18.41,"value":368200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The\nsales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."}],"balance_after":787780,"source":{"system":"sec-edgar","filing":"0001159036-26-000119","document":"wk-form4_1789173314.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1528185/000115903626000119/wk-form4_1789173314.xml","form_type":"4"}},{"id":4616538,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-09-12T00:35:17.000Z","date":"2026-09-10","kind":"sale","planned":true,"acquired":false,"shares":5412,"price":107.581,"value":582228.372,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The\nsales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $107.360 to $107.820 The Reporting Person has provided to the issuer, and will provide to any\nsecurity holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range"}],"balance_after":767780,"source":{"system":"sec-edgar","filing":"0001159036-26-000119","document":"wk-form4_1789173314.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1528185/000115903626000119/wk-form4_1789173314.xml","form_type":"4"}},{"id":4616537,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-09-12T00:35:17.000Z","date":"2026-09-10","kind":"sale","planned":true,"acquired":false,"shares":14588,"price":107.012,"value":1561091.056,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The\nsales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $106.360 to $107.350 The Reporting Person has provided to the issuer, and will provide to any\nsecurity holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range"}],"balance_after":773192,"source":{"system":"sec-edgar","filing":"0001159036-26-000119","document":"wk-form4_1789173314.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1528185/000115903626000119/wk-form4_1789173314.xml","form_type":"4"}},{"id":4616536,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-09-12T00:35:17.000Z","date":"2026-09-10","kind":"exercise","planned":true,"acquired":true,"shares":20000,"price":18.41,"value":368200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The\nsales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."}],"balance_after":787780,"source":{"system":"sec-edgar","filing":"0001159036-26-000119","document":"wk-form4_1789173314.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1528185/000115903626000119/wk-form4_1789173314.xml","form_type":"4"}},{"id":4616535,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-09-12T00:35:17.000Z","date":"2026-09-09","kind":"sale","planned":true,"acquired":false,"shares":100,"price":108.67,"value":10867.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The\nsales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."}],"balance_after":767780,"source":{"system":"sec-edgar","filing":"0001159036-26-000119","document":"wk-form4_1789173314.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1528185/000115903626000119/wk-form4_1789173314.xml","form_type":"4"}},{"id":4616534,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-09-12T00:35:17.000Z","date":"2026-09-09","kind":"sale","planned":true,"acquired":false,"shares":6596,"price":107.821,"value":711187.316,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The\nsales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $107.640 to $108.290. The Reporting Person has provided to the issuer, and will provide to any security\nholder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":767880,"source":{"system":"sec-edgar","filing":"0001159036-26-000119","document":"wk-form4_1789173314.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1528185/000115903626000119/wk-form4_1789173314.xml","form_type":"4"}},{"id":4616533,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-09-12T00:35:17.000Z","date":"2026-09-09","kind":"sale","planned":true,"acquired":false,"shares":13304,"price":107.222,"value":1426481.488,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The\nsales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $106.640 to $107.632. The Reporting Person has provided to the issuer, and will provide to any security\nholder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":774476,"source":{"system":"sec-edgar","filing":"0001159036-26-000119","document":"wk-form4_1789173314.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1528185/000115903626000119/wk-form4_1789173314.xml","form_type":"4"}},{"id":4616532,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-09-12T00:35:17.000Z","date":"2026-09-09","kind":"exercise","planned":true,"acquired":true,"shares":20000,"price":18.41,"value":368200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The\nsales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."}],"balance_after":787780,"source":{"system":"sec-edgar","filing":"0001159036-26-000119","document":"wk-form4_1789173314.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1528185/000115903626000119/wk-form4_1789173314.xml","form_type":"4"}},{"id":681850,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Option to Purchase Common Stock","published_at":"2026-08-20T00:01:15.000Z","date":"2026-08-19","kind":"exercise","planned":true,"acquired":false,"shares":20000,"price":18.41,"value":368200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales\nof common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant\nwas February 14, 2018."}],"balance_after":141552,"derivative":{"exercise_price":18.41,"expiration_date":"2028-02-14","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001159036-26-000108","document":"wk-form4_1787184072.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000108/wk-form4_1787184072.xml","form_type":"4"}},{"id":681849,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Option to Purchase Common Stock","published_at":"2026-08-20T00:01:15.000Z","date":"2026-08-18","kind":"exercise","planned":true,"acquired":false,"shares":20000,"price":18.41,"value":368200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales\nof common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant\nwas February 14, 2018."}],"balance_after":161552,"derivative":{"exercise_price":18.41,"expiration_date":"2028-02-14","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001159036-26-000108","document":"wk-form4_1787184072.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000108/wk-form4_1787184072.xml","form_type":"4"}},{"id":681848,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Option to Purchase Common Stock","published_at":"2026-08-20T00:01:15.000Z","date":"2026-08-17","kind":"exercise","planned":true,"acquired":false,"shares":20000,"price":18.41,"value":368200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales\nof common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant\nwas February 14, 2018."}],"balance_after":181552,"derivative":{"exercise_price":18.41,"expiration_date":"2028-02-14","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001159036-26-000108","document":"wk-form4_1787184072.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000108/wk-form4_1787184072.xml","form_type":"4"}},{"id":681847,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-08-20T00:01:15.000Z","date":"2026-08-19","kind":"sale","planned":true,"acquired":false,"shares":3200,"price":107.765,"value":344848.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales\nof common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $107.69 to $107.900 The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":767780,"source":{"system":"sec-edgar","filing":"0001159036-26-000108","document":"wk-form4_1787184072.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000108/wk-form4_1787184072.xml","form_type":"4"}},{"id":681846,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-08-20T00:01:15.000Z","date":"2026-08-19","kind":"sale","planned":true,"acquired":false,"shares":9600,"price":107.224,"value":1029350.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales\nof common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $106.69 to $107.680 The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":770980,"source":{"system":"sec-edgar","filing":"0001159036-26-000108","document":"wk-form4_1787184072.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000108/wk-form4_1787184072.xml","form_type":"4"}},{"id":681845,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-08-20T00:01:15.000Z","date":"2026-08-19","kind":"sale","planned":true,"acquired":false,"shares":7200,"price":106.358,"value":765777.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales\nof common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $105.69 to $106.680 The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":780580,"source":{"system":"sec-edgar","filing":"0001159036-26-000108","document":"wk-form4_1787184072.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000108/wk-form4_1787184072.xml","form_type":"4"}},{"id":681844,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-08-20T00:01:15.000Z","date":"2026-08-19","kind":"exercise","planned":true,"acquired":true,"shares":20000,"price":18.41,"value":368200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales\nof common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."}],"balance_after":787780,"source":{"system":"sec-edgar","filing":"0001159036-26-000108","document":"wk-form4_1787184072.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000108/wk-form4_1787184072.xml","form_type":"4"}},{"id":681843,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-08-20T00:01:15.000Z","date":"2026-08-18","kind":"sale","planned":true,"acquired":false,"shares":9400,"price":104.874,"value":985815.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales\nof common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $104.585 to $105.080 The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":767780,"source":{"system":"sec-edgar","filing":"0001159036-26-000108","document":"wk-form4_1787184072.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000108/wk-form4_1787184072.xml","form_type":"4"}},{"id":681842,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-08-20T00:01:15.000Z","date":"2026-08-18","kind":"sale","planned":true,"acquired":false,"shares":4897,"price":104.11,"value":509826.67,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales\nof common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $103.570 to $104.550. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":777180,"source":{"system":"sec-edgar","filing":"0001159036-26-000108","document":"wk-form4_1787184072.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000108/wk-form4_1787184072.xml","form_type":"4"}},{"id":681841,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-08-20T00:01:15.000Z","date":"2026-08-18","kind":"sale","planned":true,"acquired":false,"shares":5703,"price":103.083,"value":587882.349,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales\nof common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $102.550 to $103.540. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":782077,"source":{"system":"sec-edgar","filing":"0001159036-26-000108","document":"wk-form4_1787184072.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000108/wk-form4_1787184072.xml","form_type":"4"}},{"id":681840,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-08-20T00:01:15.000Z","date":"2026-08-18","kind":"exercise","planned":true,"acquired":true,"shares":20000,"price":18.41,"value":368200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales\nof common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."}],"balance_after":787780,"source":{"system":"sec-edgar","filing":"0001159036-26-000108","document":"wk-form4_1787184072.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000108/wk-form4_1787184072.xml","form_type":"4"}},{"id":681839,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-08-20T00:01:15.000Z","date":"2026-08-17","kind":"sale","planned":true,"acquired":false,"shares":7500,"price":103.482,"value":776115.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales\nof common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $103.160 to $104.010. The Reporting Person has provided to the issuer, and will provide to any security\nholder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":767780,"source":{"system":"sec-edgar","filing":"0001159036-26-000108","document":"wk-form4_1787184072.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000108/wk-form4_1787184072.xml","form_type":"4"}},{"id":681838,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-08-20T00:01:15.000Z","date":"2026-08-17","kind":"sale","planned":true,"acquired":false,"shares":9000,"price":102.553,"value":922977.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales\nof common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $102.140 to $103.050. The Reporting Person has provided to the issuer, and will provide to any security\nholder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":775280,"source":{"system":"sec-edgar","filing":"0001159036-26-000108","document":"wk-form4_1787184072.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000108/wk-form4_1787184072.xml","form_type":"4"}},{"id":681837,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-08-20T00:01:15.000Z","date":"2026-08-17","kind":"sale","planned":true,"acquired":false,"shares":2100,"price":101.766,"value":213708.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales\nof common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $101.140 to $102.120. The Reporting Person has provided to the issuer, and will provide to any security\nholder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":784280,"source":{"system":"sec-edgar","filing":"0001159036-26-000108","document":"wk-form4_1787184072.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000108/wk-form4_1787184072.xml","form_type":"4"}},{"id":681836,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-08-20T00:01:15.000Z","date":"2026-08-17","kind":"sale","planned":true,"acquired":false,"shares":500,"price":100.457,"value":50228.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales\nof common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $99.980 to $100.780. The Reporting Person has provided to the issuer, and will provide to any security\nholder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":786380,"source":{"system":"sec-edgar","filing":"0001159036-26-000108","document":"wk-form4_1787184072.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000108/wk-form4_1787184072.xml","form_type":"4"}},{"id":681835,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-08-20T00:01:15.000Z","date":"2026-08-17","kind":"sale","planned":true,"acquired":false,"shares":900,"price":98.958,"value":89062.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales\nof common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $98.580 to $99.210. The Reporting Person has provided to the issuer, and will provide to any security\nholder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":786880,"source":{"system":"sec-edgar","filing":"0001159036-26-000108","document":"wk-form4_1787184072.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000108/wk-form4_1787184072.xml","form_type":"4"}},{"id":681834,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-08-20T00:01:15.000Z","date":"2026-08-17","kind":"exercise","planned":true,"acquired":true,"shares":20000,"price":18.41,"value":368200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales\nof common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."}],"balance_after":787780,"source":{"system":"sec-edgar","filing":"0001159036-26-000108","document":"wk-form4_1787184072.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000108/wk-form4_1787184072.xml","form_type":"4"}},{"id":712025,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Option to Purchase Common Stock","published_at":"2026-07-09T21:19:34.000Z","date":"2026-07-08","kind":"exercise","planned":true,"acquired":false,"shares":1923,"price":12.07,"value":23210.61,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 22, 2017."}],"balance_after":0,"derivative":{"exercise_price":12.07,"expiration_date":"2027-02-22","underlying":"Common Stock","underlying_shares":1923},"source":{"system":"sec-edgar","filing":"0001159036-26-000100","document":"wk-form4_1783631972.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000100/wk-form4_1783631972.xml","form_type":"4"}},{"id":712024,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-07-09T21:19:34.000Z","date":"2026-07-08","kind":"sale","planned":true,"acquired":false,"shares":1035,"price":80.187,"value":82993.545,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $79.710 to $80.490. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":767780,"source":{"system":"sec-edgar","filing":"0001159036-26-000100","document":"wk-form4_1783631972.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000100/wk-form4_1783631972.xml","form_type":"4"}},{"id":712023,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-07-09T21:19:34.000Z","date":"2026-07-08","kind":"sale","planned":true,"acquired":false,"shares":888,"price":79.276,"value":70397.088,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $78.710 to $79.700. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":768815,"source":{"system":"sec-edgar","filing":"0001159036-26-000100","document":"wk-form4_1783631972.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000100/wk-form4_1783631972.xml","form_type":"4"}},{"id":712022,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-07-09T21:19:34.000Z","date":"2026-07-08","kind":"exercise","planned":true,"acquired":true,"shares":1923,"price":12.07,"value":23210.61,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027."}],"balance_after":769703,"source":{"system":"sec-edgar","filing":"0001159036-26-000100","document":"wk-form4_1783631972.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000100/wk-form4_1783631972.xml","form_type":"4"}},{"id":752489,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Option to Purchase Common Stock","published_at":"2026-06-04T00:06:58.000Z","date":"2026-06-03","kind":"exercise","planned":true,"acquired":false,"shares":10000,"price":12.07,"value":120700.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 22, 2017."}],"balance_after":1923,"derivative":{"exercise_price":12.07,"expiration_date":"2027-02-22","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001159036-26-000074","document":"wk-form4_1780531615.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000074/wk-form4_1780531615.xml","form_type":"4"}},{"id":752488,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Option to Purchase Common Stock","published_at":"2026-06-04T00:06:58.000Z","date":"2026-06-02","kind":"exercise","planned":true,"acquired":false,"shares":20000,"price":12.07,"value":241400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 22, 2017."}],"balance_after":11923,"derivative":{"exercise_price":12.07,"expiration_date":"2027-02-22","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001159036-26-000074","document":"wk-form4_1780531615.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000074/wk-form4_1780531615.xml","form_type":"4"}},{"id":752487,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Option to Purchase Common Stock","published_at":"2026-06-04T00:06:58.000Z","date":"2026-06-01","kind":"exercise","planned":true,"acquired":false,"shares":20000,"price":12.07,"value":241400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 22, 2017."}],"balance_after":31923,"derivative":{"exercise_price":12.07,"expiration_date":"2027-02-22","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001159036-26-000074","document":"wk-form4_1780531615.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000074/wk-form4_1780531615.xml","form_type":"4"}},{"id":752486,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-06-04T00:06:58.000Z","date":"2026-06-03","kind":"sale","planned":true,"acquired":false,"shares":6100,"price":69.692,"value":425121.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $69.120 to $70.050. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":767780,"source":{"system":"sec-edgar","filing":"0001159036-26-000074","document":"wk-form4_1780531615.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000074/wk-form4_1780531615.xml","form_type":"4"}},{"id":752485,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-06-04T00:06:58.000Z","date":"2026-06-03","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":68.736,"value":137472.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $68.100 to $69.080. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":773880,"source":{"system":"sec-edgar","filing":"0001159036-26-000074","document":"wk-form4_1780531615.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000074/wk-form4_1780531615.xml","form_type":"4"}},{"id":752484,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-06-04T00:06:58.000Z","date":"2026-06-03","kind":"sale","planned":true,"acquired":false,"shares":1500,"price":67.675,"value":101512.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $67.090 to $68.000. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":775880,"source":{"system":"sec-edgar","filing":"0001159036-26-000074","document":"wk-form4_1780531615.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000074/wk-form4_1780531615.xml","form_type":"4"}},{"id":752483,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-06-04T00:06:58.000Z","date":"2026-06-03","kind":"sale","planned":true,"acquired":false,"shares":400,"price":66.368,"value":26547.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $66.000 to $66.770. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":777380,"source":{"system":"sec-edgar","filing":"0001159036-26-000074","document":"wk-form4_1780531615.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000074/wk-form4_1780531615.xml","form_type":"4"}},{"id":752482,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-06-04T00:06:58.000Z","date":"2026-06-03","kind":"exercise","planned":true,"acquired":true,"shares":10000,"price":12.07,"value":120700.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027."}],"balance_after":777780,"source":{"system":"sec-edgar","filing":"0001159036-26-000074","document":"wk-form4_1780531615.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000074/wk-form4_1780531615.xml","form_type":"4"}},{"id":752481,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-06-04T00:06:58.000Z","date":"2026-06-02","kind":"sale","planned":true,"acquired":false,"shares":3400,"price":66.745,"value":226933.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $66.630 to $67.180. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":767780,"source":{"system":"sec-edgar","filing":"0001159036-26-000074","document":"wk-form4_1780531615.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000074/wk-form4_1780531615.xml","form_type":"4"}},{"id":752480,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-06-04T00:06:58.000Z","date":"2026-06-02","kind":"sale","planned":true,"acquired":false,"shares":16600,"price":66.314,"value":1100812.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $65.630 to $66.625. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":771180,"source":{"system":"sec-edgar","filing":"0001159036-26-000074","document":"wk-form4_1780531615.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000074/wk-form4_1780531615.xml","form_type":"4"}},{"id":752479,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-06-04T00:06:58.000Z","date":"2026-06-02","kind":"exercise","planned":true,"acquired":true,"shares":20000,"price":12.07,"value":241400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027."}],"balance_after":787780,"source":{"system":"sec-edgar","filing":"0001159036-26-000074","document":"wk-form4_1780531615.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000074/wk-form4_1780531615.xml","form_type":"4"}},{"id":752478,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-06-04T00:06:58.000Z","date":"2026-06-01","kind":"sale","planned":true,"acquired":false,"shares":5401,"price":68.346,"value":369136.746,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $67.840 to $68.820. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":767780,"source":{"system":"sec-edgar","filing":"0001159036-26-000074","document":"wk-form4_1780531615.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000074/wk-form4_1780531615.xml","form_type":"4"}},{"id":752477,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-06-04T00:06:58.000Z","date":"2026-06-01","kind":"sale","planned":true,"acquired":false,"shares":12989,"price":67.41,"value":875588.49,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $66.840 to $67.830. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":773181,"source":{"system":"sec-edgar","filing":"0001159036-26-000074","document":"wk-form4_1780531615.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000074/wk-form4_1780531615.xml","form_type":"4"}},{"id":752476,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-06-04T00:06:58.000Z","date":"2026-06-01","kind":"sale","planned":true,"acquired":false,"shares":1610,"price":66.388,"value":106884.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $65.840 to $66.830. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":786170,"source":{"system":"sec-edgar","filing":"0001159036-26-000074","document":"wk-form4_1780531615.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000074/wk-form4_1780531615.xml","form_type":"4"}},{"id":752475,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-06-04T00:06:58.000Z","date":"2026-06-01","kind":"exercise","planned":true,"acquired":true,"shares":20000,"price":12.07,"value":241400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027."}],"balance_after":787780,"source":{"system":"sec-edgar","filing":"0001159036-26-000074","document":"wk-form4_1780531615.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000074/wk-form4_1780531615.xml","form_type":"4"}},{"id":781214,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Option to Purchase Common Stock","published_at":"2026-05-13T21:50:19.000Z","date":"2026-05-13","kind":"exercise","planned":true,"acquired":false,"shares":10000,"price":12.07,"value":120700.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 22, 2017."}],"balance_after":51923,"derivative":{"exercise_price":12.07,"expiration_date":"2027-02-22","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001159036-26-000070","document":"wk-form4_1778709013.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000070/wk-form4_1778709013.xml","form_type":"4"}},{"id":781213,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Option to Purchase Common Stock","published_at":"2026-05-13T21:50:19.000Z","date":"2026-05-12","kind":"exercise","planned":true,"acquired":false,"shares":20000,"price":12.07,"value":241400.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 22, 2017."}],"balance_after":61923,"derivative":{"exercise_price":12.07,"expiration_date":"2027-02-22","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001159036-26-000070","document":"wk-form4_1778709013.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000070/wk-form4_1778709013.xml","form_type":"4"}},{"id":781212,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Option to Purchase Common Stock","published_at":"2026-05-13T21:50:19.000Z","date":"2026-05-11","kind":"exercise","planned":true,"acquired":false,"shares":20000,"price":12.07,"value":241400.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 22, 2017."}],"balance_after":81923,"derivative":{"exercise_price":12.07,"expiration_date":"2027-02-22","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001159036-26-000070","document":"wk-form4_1778709013.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000070/wk-form4_1778709013.xml","form_type":"4"}},{"id":781211,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-05-13T21:50:19.000Z","date":"2026-05-13","kind":"sale","planned":true,"acquired":false,"shares":600,"price":70.812,"value":42487.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $70.480 to $71.220. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":767780,"source":{"system":"sec-edgar","filing":"0001159036-26-000070","document":"wk-form4_1778709013.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000070/wk-form4_1778709013.xml","form_type":"4"}},{"id":781210,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-05-13T21:50:19.000Z","date":"2026-05-13","kind":"sale","planned":true,"acquired":false,"shares":3950,"price":69.787,"value":275658.65,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $69.450 to $70.050. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":768380,"source":{"system":"sec-edgar","filing":"0001159036-26-000070","document":"wk-form4_1778709013.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000070/wk-form4_1778709013.xml","form_type":"4"}},{"id":781209,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-05-13T21:50:19.000Z","date":"2026-05-13","kind":"sale","planned":true,"acquired":false,"shares":3350,"price":68.88,"value":230748.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $68.450 to $69.440. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":772330,"source":{"system":"sec-edgar","filing":"0001159036-26-000070","document":"wk-form4_1778709013.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000070/wk-form4_1778709013.xml","form_type":"4"}},{"id":781208,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-05-13T21:50:19.000Z","date":"2026-05-13","kind":"sale","planned":true,"acquired":false,"shares":2100,"price":68.102,"value":143014.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $67.450 to $68.440. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":775680,"source":{"system":"sec-edgar","filing":"0001159036-26-000070","document":"wk-form4_1778709013.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000070/wk-form4_1778709013.xml","form_type":"4"}},{"id":781207,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-05-13T21:50:19.000Z","date":"2026-05-13","kind":"exercise","planned":true,"acquired":true,"shares":10000,"price":12.07,"value":120700.0,"ownership":{"direct":true},"balance_after":777780,"source":{"system":"sec-edgar","filing":"0001159036-26-000070","document":"wk-form4_1778709013.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000070/wk-form4_1778709013.xml","form_type":"4"}},{"id":781206,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-05-13T21:50:19.000Z","date":"2026-05-12","kind":"sale","planned":true,"acquired":false,"shares":2800,"price":73.121,"value":204738.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $72.810 to $73.770. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":767780,"source":{"system":"sec-edgar","filing":"0001159036-26-000070","document":"wk-form4_1778709013.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000070/wk-form4_1778709013.xml","form_type":"4"}},{"id":781205,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-05-13T21:50:19.000Z","date":"2026-05-12","kind":"sale","planned":true,"acquired":false,"shares":5900,"price":72.148,"value":425673.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $71.805 to $72.780. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":770580,"source":{"system":"sec-edgar","filing":"0001159036-26-000070","document":"wk-form4_1778709013.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000070/wk-form4_1778709013.xml","form_type":"4"}},{"id":781204,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-05-13T21:50:19.000Z","date":"2026-05-12","kind":"sale","planned":true,"acquired":false,"shares":9802,"price":71.37,"value":699568.74,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $70.800 to $71.795 The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":776480,"source":{"system":"sec-edgar","filing":"0001159036-26-000070","document":"wk-form4_1778709013.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000070/wk-form4_1778709013.xml","form_type":"4"}},{"id":781203,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-05-13T21:50:19.000Z","date":"2026-05-12","kind":"sale","planned":true,"acquired":false,"shares":1398,"price":70.287,"value":98261.226,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $69.740 to $70.700. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":786282,"source":{"system":"sec-edgar","filing":"0001159036-26-000070","document":"wk-form4_1778709013.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000070/wk-form4_1778709013.xml","form_type":"4"}},{"id":781202,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-05-13T21:50:19.000Z","date":"2026-05-12","kind":"sale","planned":true,"acquired":false,"shares":100,"price":67.85,"value":6785.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027."}],"balance_after":787680,"source":{"system":"sec-edgar","filing":"0001159036-26-000070","document":"wk-form4_1778709013.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000070/wk-form4_1778709013.xml","form_type":"4"}},{"id":781201,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-05-13T21:50:19.000Z","date":"2026-05-12","kind":"exercise","planned":true,"acquired":true,"shares":20000,"price":12.07,"value":241400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027."}],"balance_after":787780,"source":{"system":"sec-edgar","filing":"0001159036-26-000070","document":"wk-form4_1778709013.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000070/wk-form4_1778709013.xml","form_type":"4"}},{"id":781200,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-05-13T21:50:19.000Z","date":"2026-05-11","kind":"sale","planned":true,"acquired":false,"shares":6700,"price":66.327,"value":444390.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $66.040 to $66.720. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":767780,"source":{"system":"sec-edgar","filing":"0001159036-26-000070","document":"wk-form4_1778709013.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000070/wk-form4_1778709013.xml","form_type":"4"}},{"id":781199,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-05-13T21:50:19.000Z","date":"2026-05-11","kind":"sale","planned":true,"acquired":false,"shares":3575,"price":65.458,"value":234012.35,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $65.030 to $66.010. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":774480,"source":{"system":"sec-edgar","filing":"0001159036-26-000070","document":"wk-form4_1778709013.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000070/wk-form4_1778709013.xml","form_type":"4"}},{"id":781198,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-05-13T21:50:19.000Z","date":"2026-05-11","kind":"sale","planned":true,"acquired":false,"shares":9725,"price":64.631,"value":628536.475,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $64.030 to $65.010. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":778055,"source":{"system":"sec-edgar","filing":"0001159036-26-000070","document":"wk-form4_1778709013.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000070/wk-form4_1778709013.xml","form_type":"4"}},{"id":781197,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-05-13T21:50:19.000Z","date":"2026-05-11","kind":"exercise","planned":true,"acquired":true,"shares":20000,"price":12.07,"value":241400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027."}],"balance_after":787780,"source":{"system":"sec-edgar","filing":"0001159036-26-000070","document":"wk-form4_1778709013.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000070/wk-form4_1778709013.xml","form_type":"4"}},{"id":813698,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Option to Purchase Common Stock","published_at":"2026-04-07T21:13:42.000Z","date":"2026-04-06","kind":"exercise","planned":true,"acquired":false,"shares":10000,"price":12.07,"value":120700.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 22, 2017."}],"balance_after":101923,"derivative":{"exercise_price":12.07,"expiration_date":"2027-02-22","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001159036-26-000048","document":"wk-form4_1775596415.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000048/wk-form4_1775596415.xml","form_type":"4"}},{"id":813697,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-04-07T21:13:42.000Z","date":"2026-04-06","kind":"sale","planned":true,"acquired":false,"shares":4100,"price":64.015,"value":262461.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $63.750 to $64.330. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":767780,"source":{"system":"sec-edgar","filing":"0001159036-26-000048","document":"wk-form4_1775596415.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000048/wk-form4_1775596415.xml","form_type":"4"}},{"id":813696,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-04-07T21:13:42.000Z","date":"2026-04-06","kind":"sale","planned":true,"acquired":false,"shares":5900,"price":63.139,"value":372520.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $62.710 to $63.670. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":771880,"source":{"system":"sec-edgar","filing":"0001159036-26-000048","document":"wk-form4_1775596415.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000048/wk-form4_1775596415.xml","form_type":"4"}},{"id":813695,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-04-07T21:13:42.000Z","date":"2026-04-06","kind":"exercise","planned":true,"acquired":true,"shares":10000,"price":12.07,"value":120700.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027."}],"balance_after":777780,"source":{"system":"sec-edgar","filing":"0001159036-26-000048","document":"wk-form4_1775596415.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000048/wk-form4_1775596415.xml","form_type":"4"}},{"id":820563,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Option to Purchase Common Stock","published_at":"2026-04-02T22:28:38.000Z","date":"2026-04-02","kind":"exercise","planned":true,"acquired":false,"shares":20000,"price":12.07,"value":241400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 22, 2017."}],"balance_after":111923,"derivative":{"exercise_price":12.07,"expiration_date":"2027-02-22","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001159036-26-000046","document":"wk-form4_1775168915.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000046/wk-form4_1775168915.xml","form_type":"4"}},{"id":820562,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Option to Purchase Common Stock","published_at":"2026-04-02T22:28:38.000Z","date":"2026-04-01","kind":"exercise","planned":true,"acquired":false,"shares":20000,"price":12.07,"value":241400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 22, 2017."}],"balance_after":131923,"derivative":{"exercise_price":12.07,"expiration_date":"2027-02-22","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001159036-26-000046","document":"wk-form4_1775168915.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000046/wk-form4_1775168915.xml","form_type":"4"}},{"id":820561,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-04-02T22:28:38.000Z","date":"2026-04-02","kind":"sale","planned":true,"acquired":false,"shares":4200,"price":64.887,"value":272525.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $64.660 to $65.380. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":767780,"source":{"system":"sec-edgar","filing":"0001159036-26-000046","document":"wk-form4_1775168915.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000046/wk-form4_1775168915.xml","form_type":"4"}},{"id":820560,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-04-02T22:28:38.000Z","date":"2026-04-02","kind":"sale","planned":true,"acquired":false,"shares":15800,"price":64.063,"value":1012195.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $63.650 to $64.620. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":771980,"source":{"system":"sec-edgar","filing":"0001159036-26-000046","document":"wk-form4_1775168915.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000046/wk-form4_1775168915.xml","form_type":"4"}},{"id":820559,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-04-02T22:28:38.000Z","date":"2026-04-02","kind":"exercise","planned":true,"acquired":true,"shares":20000,"price":12.07,"value":241400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027."}],"balance_after":787780,"source":{"system":"sec-edgar","filing":"0001159036-26-000046","document":"wk-form4_1775168915.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000046/wk-form4_1775168915.xml","form_type":"4"}},{"id":820558,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-04-02T22:28:38.000Z","date":"2026-04-01","kind":"sale","planned":true,"acquired":false,"shares":1000,"price":65.714,"value":65714.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $65.660 to $65.860. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":767780,"source":{"system":"sec-edgar","filing":"0001159036-26-000046","document":"wk-form4_1775168915.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000046/wk-form4_1775168915.xml","form_type":"4"}},{"id":820557,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-04-02T22:28:38.000Z","date":"2026-04-01","kind":"sale","planned":true,"acquired":false,"shares":19000,"price":65.358,"value":1241802.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $64.650 to $65.640. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":768780,"source":{"system":"sec-edgar","filing":"0001159036-26-000046","document":"wk-form4_1775168915.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000046/wk-form4_1775168915.xml","form_type":"4"}},{"id":820556,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-04-02T22:28:38.000Z","date":"2026-04-01","kind":"exercise","planned":true,"acquired":true,"shares":20000,"price":12.07,"value":241400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027."}],"balance_after":787780,"source":{"system":"sec-edgar","filing":"0001159036-26-000046","document":"wk-form4_1775168915.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000046/wk-form4_1775168915.xml","form_type":"4"}},{"id":862539,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Option to Purchase Common Stock","published_at":"2026-03-04T23:56:16.000Z","date":"2026-03-04","kind":"exercise","planned":true,"acquired":false,"shares":10000,"price":12.07,"value":120700.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 22, 2017."}],"balance_after":151923,"derivative":{"exercise_price":12.07,"expiration_date":"2027-02-22","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001159036-26-000032","document":"wk-form4_1772668573.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000032/wk-form4_1772668573.xml","form_type":"4"}},{"id":862538,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Option to Purchase Common Stock","published_at":"2026-03-04T23:56:16.000Z","date":"2026-03-03","kind":"exercise","planned":true,"acquired":false,"shares":20000,"price":12.07,"value":241400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 22, 2017."}],"balance_after":161923,"derivative":{"exercise_price":12.07,"expiration_date":"2027-02-22","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001159036-26-000032","document":"wk-form4_1772668573.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000032/wk-form4_1772668573.xml","form_type":"4"}},{"id":862537,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Option to Purchase Common Stock","published_at":"2026-03-04T23:56:16.000Z","date":"2026-03-02","kind":"exercise","planned":true,"acquired":false,"shares":20000,"price":12.07,"value":241400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 22, 2017."}],"balance_after":181923,"derivative":{"exercise_price":12.07,"expiration_date":"2027-02-22","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001159036-26-000032","document":"wk-form4_1772668573.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000032/wk-form4_1772668573.xml","form_type":"4"}}],"next_cursor":"2026-03-04T23:56:16.000000Z,862537"}